Product catalog antigen listed by alphabetic starting with S
| Items 101 to 200 of 1.879 total | 19 Page(s): |
Protein
| Catalog No. | Species | Presentation | Purity | Source | |||
|---|---|---|---|---|---|---|---|
| H00056681-P01-10 | SARA1 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00056681-P01-25 | SARA1 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00051128-P01-02 | SARA2 antigen | ||||||
| Human | in vitro transl. | 2 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00051128-P01-10 | SARA2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00051128-P01-25 | SARA2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006301-P01-10 | SARS antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006301-P01-25 | SARS antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| PA1307 | SARS Envelope Protein (1-76) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.1 mg / US$ 255 | |||
| Acris Antibodies GmbH | |||||||
| PA1307X | SARS Envelope Protein (1-76) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.5 mg / US$ 555 | |||
| Acris Antibodies GmbH | |||||||
| PA1307XC | SARS Envelope Protein (1-76) antigen | ||||||
| Human | Purified | >95% | E. coli | 1 mg / ask | |||
| Acris Antibodies GmbH | |||||||
| PA1306 | SARS Matrix Protein (182-216) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.1 mg / US$ 255 | |||
| Acris Antibodies GmbH | |||||||
| PA1306X | SARS Matrix Protein (182-216) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.5 mg / US$ 555 | |||
| Acris Antibodies GmbH | |||||||
| PA1306XC | SARS Matrix Protein (182-216) antigen | ||||||
| Human | Purified | >95% | E. coli | 1 mg / ask | |||
| Acris Antibodies GmbH | |||||||
| PA1304 | SARS Nucleocapsid (1-49) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.1 mg / US$ 255 | |||
| Acris Antibodies GmbH | |||||||
| PA1304X | SARS Nucleocapsid (1-49) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.5 mg / US$ 555 | |||
| Acris Antibodies GmbH | |||||||
| PA1304XC | SARS Nucleocapsid (1-49) antigen | ||||||
| Human | Purified | >95% | E. coli | 1 mg / ask | |||
| Acris Antibodies GmbH | |||||||
| PA1305 | SARS Nucleocapsid (1-49, 192-220) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.1 mg / US$ 255 | |||
| Acris Antibodies GmbH | |||||||
| PA1305X | SARS Nucleocapsid (1-49, 192-220) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.5 mg / US$ 555 | |||
| Acris Antibodies GmbH | |||||||
| PA1305XC | SARS Nucleocapsid (1-49, 192-220) antigen | ||||||
| Human | Purified | >95% | E. coli | 1 mg / ask | |||
| Acris Antibodies GmbH | |||||||
| PA1303 | SARS Nucleocapsid (340-390) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.1 mg / US$ 255 | |||
| Acris Antibodies GmbH | |||||||
| PA1303X | SARS Nucleocapsid (340-390) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.5 mg / US$ 555 | |||
| Acris Antibodies GmbH | |||||||
| PA1303XC | SARS Nucleocapsid (340-390) antigen | ||||||
| Human | Purified | >95% | E. coli | 1 mg / ask | |||
| Acris Antibodies GmbH | |||||||
| PA1302 | SARS Spike Protein (C-term immunodominant regions) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.1 mg / US$ 255 | |||
| Acris Antibodies GmbH | |||||||
| PA1302X | SARS Spike Protein (C-term immunodominant regions) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.5 mg / US$ 555 | |||
| Acris Antibodies GmbH | |||||||
| PA1302XC | SARS Spike Protein (C-term immunodominant regions) antigen | ||||||
| Human | Purified | >95% | E. coli | 1 mg / ask | |||
| Acris Antibodies GmbH | |||||||
| PA1308 | SARS Spike Protein (mid section immunodominant regions) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.1 mg / US$ 255 | |||
| Acris Antibodies GmbH | |||||||
| PA1308X | SARS Spike Protein (mid section immunodominant regions) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.5 mg / US$ 555 | |||
| Acris Antibodies GmbH | |||||||
| PA1308XC | SARS Spike Protein (mid section immunodominant regions) antigen | ||||||
| Human | Purified | >95% | E. coli | 1 mg / ask | |||
| Acris Antibodies GmbH | |||||||
| PA1301 | SARS Spike Protein (N-term immunodominant regions) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.1 mg / US$ 255 | |||
| Acris Antibodies GmbH | |||||||
| PA1301X | SARS Spike Protein (N-term immunodominant regions) antigen | ||||||
| Human | Purified | >95% | E. coli | 0.5 mg / US$ 555 | |||
| Acris Antibodies GmbH | |||||||
| PA1301XC | SARS Spike Protein (N-term immunodominant regions) antigen | ||||||
| Human | Purified | >95% | E. coli | 1 mg / ask | |||
| Acris Antibodies GmbH | |||||||
| H00029940-Q01-10 | SART2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00029940-Q01-25 | SART2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006302-P01-10 | SAS antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006302-P01-25 | SAS antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00023328-Q01-10 | SASH1 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00023328-Q01-25 | SASH1 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006303-P01-02 | SAT antigen | ||||||
| Human | in vitro transl. | 2 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006303-P01-10 | SAT antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006303-P01-25 | SAT antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006303-Q01-10 | SAT antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006303-Q01-25 | SAT antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00023314-Q01-10 | SATB2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00023314-Q01-25 | SATB2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00060485-Q01-10 | SAV1 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00060485-Q01-25 | SAV1 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00081846-Q01-10 | SBF2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00081846-Q01-25 | SBF2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00011037-Q01-10 | SBLF antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00011037-Q01-25 | SBLF antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006307-P01-10 | SC4MOL antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006307-P01-25 | SC4MOL antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006309-Q01-10 | SC5DL antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00006309-Q01-25 | SC5DL antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00010609-Q01-10 | SC65 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00010609-Q01-25 | SC65 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00009522-P01-02 | SCAMP1 antigen | ||||||
| Human | in vitro transl. | 2 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00009522-P01-10 | SCAMP1 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00009522-P01-25 | SCAMP1 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| GTX24969 | SCAMP1 peptide antigen | ||||||
| 50 µg / --- | |||||||
| GeneTex Inc. | |||||||
| H00010066-P01-10 | SCAMP2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00010066-P01-25 | SCAMP2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| GTX24970 | SCAMP2 peptide antigen | ||||||
| 50 µg / --- | |||||||
| GeneTex Inc. | |||||||
| H00010067-Q01-10 | SCAMP3 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00010067-Q01-25 | SCAMP3 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| GTX24971 | SCAMP5 peptide antigen | ||||||
| 50 µg / --- | |||||||
| GeneTex Inc. | |||||||
| H00051282-P01-10 | SCAND1 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00051282-P01-25 | SCAND1 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| 10-288-22143F | SCAND1 antigen | ||||||
| Human | Purified | 95% | E. coli | 0.1 mg / --- | |||
| GenWay Biotech Inc. | |||||||
| 10-288-22143F-50 | SCAND1 antigen | ||||||
| Human | Purified | 95% | E. coli | 50 µg / --- | |||
| GenWay Biotech Inc. | |||||||
| H00054581-Q01-10 | SCAND2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00054581-Q01-25 | SCAND2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00054581-Q02-10 | SCAND2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00054581-Q02-25 | SCAND2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00008631-P01-10 | SCAP1 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00008631-P01-25 | SCAP1 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00008631-Q01-10 | SCAP1 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00008631-Q01-25 | SCAP1 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00008935-P01-10 | SCAP2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00008935-P01-25 | SCAP2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00008935-Q01-10 | SCAP2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00008935-Q01-25 | SCAP2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00051435-Q01-10 | SCARA3 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00051435-Q01-25 | SCARA3 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00000950-Q01-10 | SCARB2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00000950-Q01-25 | SCARB2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00000959-Q01-10 | sCD40 Ligand / TRAP antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00000959-Q01-25 | sCD40 Ligand / TRAP antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| PA151 | sCD40 Ligand / TRAP antigen | ||||||
| Human | >95% | E. coli | 2 µg / US$ 255 | ||||
| Acris Antibodies GmbH | |||||||
| PA151X | sCD40 Ligand / TRAP antigen | ||||||
| Human | >95% | E. coli | 10 µg / US$ 355 | ||||
| Acris Antibodies GmbH | |||||||
| PA216 | sCD40 Ligand / TRAP antigen | ||||||
| Mouse | >95% | E. coli | 5 µg / US$ 255 | ||||
| Acris Antibodies GmbH | |||||||
| PA216X | sCD40 Ligand / TRAP antigen | ||||||
| Mouse | >95% | E. coli | 25 µg / US$ 355 | ||||
| Acris Antibodies GmbH | |||||||
| GTX29717 | SCF protein antigen | ||||||
| 10 µg / --- | |||||||
| GeneTex Inc. | |||||||
| GTX29754 | SCF protein antigen | ||||||
| Purified | 10 µg / --- | ||||||
| GeneTex Inc. | |||||||
| H00007857-Q01-10 | SCG2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00007857-Q01-25 | SCG2 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00007356-P01-10 | SCGB1A1 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00007356-P01-25 | SCGB1A1 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00007356-P02-10 | SCGB1A1 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00007356-P02-25 | SCGB1A1 antigen | ||||||
| Human | in vitro transl. | 25 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| H00004250-P01-10 | SCGB2A2 antigen | ||||||
| Human | in vitro transl. | 10 µg / --- | |||||
| Abnova Taiwan Corp. | |||||||
| Items 101 to 200 of 1.879 total | 19 Page(s): |



